Medical materials company Instrumentation Laboratory Co. reports that the U.S. Food and Drug Administration has given the Bedford-based company approval to sell its test for determining the ...
Hospitalized patients with various underlying illnesses are routinely given parenterally administered unfractionated heparin (UFH) in order to prevent and/or treat thromboembolic events. In some cases ...
The peculiar heparin behavior started about 6 months ago. Dosing that had been reliable countless times in the cath lab was failing to get the activated clotting time (ACT) to target, forcing extra ...
Sponsored by: Diagnostica Stago, Inc. The first step in thwarting devastating complications is to maintain a high index of clinical suspicion by an accurate clinical scoring assessment using the 4T’s ...
Zacks Small Cap Research on MSN
CVKD acquires 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT)
By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results